Pharmaceutical

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.

Aug 17, 2024 - 04:00
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
The Phase III inMIND trial evaluating Monjuvi as a combination treatment in relapsed/ refractory follicular lymphoma met its primary endpoint.
Read the original article

Tags:

Previous Article

Bavarian Nordic seeks authorisation for mpox vaccine’s use in adolescents

Next Article

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

DF-4101 by AbbVie for Renal Cell Carcinoma: Likelihood ...

Apr 21, 2024

STAT+: Acelyrin, a rare IPO success, stumbles in its first big test

STAT+: Acelyrin, a rare IPO success, stumbles in its fi...

Sep 12, 2023

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023